Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drugmaker KV Pharmaceutical
So what: If you could have timed this move just right, there was a lot of money to be made in just a few hours as KV took a nosedive and then recovered all of those losses. Volume is nearly double normal with more than two hours left in the trading day, but there wasn't a big sale or purchase that prompted today's move.
Now what: Investors are likely trying to decipher what to do with this stock after it popped earlier this week on revenue projections for Makena. Since then, doctors have been outraged by the plan to charge $1,500 for the drug, so there could be pressure to reduce prices along with subsidizing low-income customers. After the meteoric rise KV has been on since Makena was approved, I am going to give it a little time to breathe before jumping in. I don't want to be on the wrong side of a correction if the company falls short of increasing expectations.
Interested in more info on KV Pharmaceutical? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Dow's Run Is Not Done
The Dow submits its second down week of 2012.
These 5 Companies Have Dominated 2012
The first three weeks of the year have been very good to shareholders in these five companies.
2012 Preview: K-V Pharmaceuticals
Here's what the new year has in store for K-V Pharmaceuticals.